Lymph node-positive prostate cancer: Current issues, emerging technology and impact on clinical outcome

Expert Review of Anticancer Therapy

Volumn 11, Issue 9, 2011, Pages 1457-1469

  Adams, Julia ^a   Cheng, Liang ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cancer volume; dedifferentiation; metastasis; pelvic lymphadenectomy; prognosis; prostate; sentinel node; staging and classification

Indexed keywords

CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CELL DEDIFFERENTIATION; CIRCULATING TUMOR CELL; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; LYMPH NODE METASTASIS; MACROMETASTASIS; METASTASIS; MICROMETASTASIS; MOLECULAR IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PELVIS LYMPHADENECTOMY; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW; SENTINEL LYMPH NODE; TUMOR VOLUME;

HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 80053018951     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.11.104     Document Type: Review

References (150)

1. von Bodman C, Godoy G, Chade DC et al. Predicting biochemical recurrence-free survival for patients with positive pelvic lymph nodes at radical prostatectomy. J. Urol. 184(1), 143-148 (2010).
2. Cheng L, Zincke H, Blute ML, Bergstralh EJ, Scherer B, Bostwick DG. Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer 91(1), 66-73 (2001). (Pubitemid 32052615)
3. Fleischmann A, Schobinger S, Markwalder R et al. Prognostic factors in lymph node metastases of prostatic cancer patients: the size of the metastases but not extranodal extension independently predicts survival. Histopathology 53(4), 468-475 (2008).
4. Gjertson CK, Asher KP, Sclar JD et al. Local control and long-term disease-free survival for stage D1 (T2-T4N1-N2M0) prostate cancer after radical prostatectomy in the PSA era. Urology 70(4), 723-727 (2007). (Pubitemid 350030211)
5. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J. Urol. 167(2 Pt 1), 528-534 (2002). (Pubitemid 34074521)
6. Seay TM, Blute MC, Zincke H. Radical prostatectomy and early adjuvant hormonal therapy for pTxN+ adenocarcinoma of the prostate. Urology 50(6), 833-837 (1997). (Pubitemid 128713173)
7. Tokuda Y, Carlino LJ, Gopalan A et al. Prostate cancer topography and patterns of lymph node metastasis. Am. J. Surg. Pathol. 34(12), 1862-1867 (2010).
8. Briganti A, Chun FK, Salonia A et al. Complications and other surgical outcomes associated with extended pelvic lymphadenectomy in men with localized prostate cancer. Eur. Urol. 50(5), 1006-1013 (2006). (Pubitemid 44486500)
9. Briganti A, Blute ML, Eastham JH et al. Pelvic lymph node dissection in prostate cancer. Eur. Urol. 55(6), 1251-1265 (2009).
10. Boorjian SA, Thompson RH, Siddiqui S et al. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. J. Urol. 178(3 Pt 1), 864-871 (2007). (Pubitemid 47211081)
11. Boormans JL, Wildhagen MF, Bangma CH, Verhagen PC, van Leenders GJ. Histopathological characteristics of lymph node metastases predict cancer-specific survival in node-positive prostate cancer. BJU Int. 102(11), 1589-1593 (2008).
12. Ghavamian R, Bergstralh EJ, Blute ML, Slezak J, Zincke H. Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: a matched comparison. J. Urol. 161(4), 1223-1228 (1999). (Pubitemid 29426122)
13. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N. Engl. J. Med. 341(24), 1781-1788 (1999).
14. Messing EM, Manola J, Yao J et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol. 7(6), 472-479 (2006). (Pubitemid 43779173)
15. Zwergel U, Lehmann J, Wullich B et al. Lymph node positive prostate cancer: long-term survival data after radical prostatectomy. J. Urol. 171(3), 1128-1131 (2004). (Pubitemid 38327541)
16. Daneshmand S, Quek ML, Stein JP et al. Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. J. Urol. 172(6 Pt 1), 2252-2255 (2004). (Pubitemid 39507502)
17. Cai T, Nesi G, Tinacci G et al. Clinical importance of lymph node density in predicting outcome of prostate cancer patients. J. Surg. Res. 167(2), 267-272 (2011).
18. Cheng L, Bergstralh EJ, Cheville JC et al. Cancer volume of lymph node metastasis predicts progression in prostate cancer. Am. J. Surg. Pathol. 22(12), 1491-1500 (1998). (Pubitemid 28550644)
19. Cheng L, Jones TD, Lin H et al. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma. J. Urol. 174(6), 2181-2185 (2005). (Pubitemid 41611770)
20. Cheng L, Pisansky TM, Ramnani DM et al. Extranodal extension in lymph node-positive prostate cancer. Mod. Pathol. 13(2), 113-118 (2000). (Pubitemid 30109096)
21. Cheng L, Slezak J, Bergstralh EJ et al. Dedifferentiation in the metastatic progression of prostate carcinoma. Cancer 86(4), 657-663 (1999). (Pubitemid 29379412)
22. Eichelberger LE, Koch MO, Eble JN, Ulbright TM, Juliar BE, Cheng L. Maximum tumor diameter is an independent predictor of prostate-specific antigen recurrence in prostate cancer. Mod. Pathol. 18(7), 886-890 (2005). (Pubitemid 41059947)
23. Fujisawa M, Miyake H. Significance of micrometastases in prostate cancer. Surg. Oncol. 17(3), 247-252 (2008).
24. Hofer MD, Kuefer R, Huang W et al. Prognostic factors in lymph node-positive prostate cancer. Urology 67(5), 1016-1021 (2006). (Pubitemid 43956399)
25. Edge S, B, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. American Joint Committee on Cancer Staging Manual. Springer, NY, USA (2010).
26. Greene FL, Page DL, Fleming ID et al. American Joint Committee on Cancer Staging Manual. Springer, NY, USA (2002).
27. Chang SS, Amin MB. Utilizing the tumor-node-metastasis staging for prostate cancer: the sixth edition, 2002. CA Cancer J. Clin. 58(1), 54-59 (2008).
28. Berney DM, Wheeler TM, Grignon DJ et al. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 4: seminal vesicles and lymph nodes. Mod. Pathol. 24(1), 39-47 (2011).
29. Barth PJ, Gerharz EW, Ramaswamy A, Riedmiller H. The influence of lymph node counts on the detection of pelvic lymph node metastasis in prostate cancer. Pathol. Res. Pract. 195(9), 633-636 (1999). (Pubitemid 29431451)
30. Epstein JI, Amin M, Boccon-Gibod L et al. Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens. Scand. J. Urol. Nephrol. Suppl. 216, 34-63 (2005).
31. Weingartner K, Ramaswamy A, Bittinger A, Gerharz EW, Voge D, Riedmiller H. Anatomical basis for pelvic lymphadenectomy in prostate cancer: results of an autopsy study and implications for the clinic. J. Urol. 156(6), 1969-1971 (1996). (Pubitemid 26378028)
32. Wawroschek F, Wagner T, Hamm M et al. The influence of serial sections, immunohistochemistry, and extension of pelvic lymph node dissection on the lymph node status in clinically localized prostate cancer. Eur. Urol. 43(2), 132-137 (2003). (Pubitemid 36221965)
33. Epstein JI, Kuhajda FP, Lieberman PH. Prostate-specific acid phosphatase immunoreactivity in adenocarcinomas of the urinary bladder. Hum. Pathol. 17(9), 939-942 (1986). (Pubitemid 17184320)
34. Sung MT, Cheng L. Contemporary approaches for processing and handling of radical prostactomy specimens. Histol. Histopathol. 25(2), 259-265 (2010).
35. Walz J, Chun FK, Klein EA et al. Nomogram predicting the probability of early recurrence after radical prostatectomy for prostate cancer. J. Urol. 181(2), 601-608 (2009).
36. Winstanley AM, Sandison A, Bott SR, Dogan A, Parkinson MC. Incidental findings in pelvic lymph nodes at radical prostatectomy. J. Clin. Pathol. 55(8), 623-626 (2002).
37. Hyndman ME, Mullins JK, Pavlovich CP. Pelvic node dissection in prostate cancer: extended, limited, or not at all? Curr. Opin. Urol. 20(3), 211-217 (2010).
38. Stein JP, Penson DF, Cai J et al. Radical cystectomy with extended lymphadenectomy: evaluating separate package versus en bloc submission for node positive bladder cancer. J. Urol. 177(3), 876-881; discussion 881-872 (2007).
39. Bochner BH, Herr HW, Reuter VE. Impact of separate versus en bloc pelvic lymph node dissection on the number of lymph nodes retrieved in cystectomy specimens. J. Urol. 166(6), 2295-2296 (2001). (Pubitemid 33065278)
40. Makarov DV, Trock BJ, Humphreys EB et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 69(6), 1095-1101 (2007). (Pubitemid 46891611)
41. Cagiannos I, Karakiewicz P, Eastham JA et al. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J. Urol. 170(5), 1798-1803 (2003). (Pubitemid 37254931)
42. Allaf ME, Palapattu GS, Trock BJ, Carter HB, Walsh PC. Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer. J. Urol. 172(5 Pt 1), 1840-1844 (2004). (Pubitemid 39363069)
43. Heidenreich A, Ohlmann CH, Polyakov S. Anatomical extent of pelvic lymphadenectomy in patients undergoing radical prostatectomy. Eur. Urol. 52(1), 29-37 (2007). (Pubitemid 46803038)
44. Masterson TA, Bianco FJ Jr, Vickers AJ et al. The association between total and positive lymph node counts, and disease progression in clinically localized prostate cancer. J. Urol. 175(4), 1320-1325 (2006).
45. Heidenreich A, Varga Z, Von Knobloch R. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J. Urol. 167(4), 1681-1686 (2002). (Pubitemid 34240702)
46. Touijer K, Rabbani F, Otero JR et al. Standard versus limited pelvic lymph node dissection for prostate cancer in patients with a predicted probability of nodal metastasis greater than 1%. J. Urol. 178(1), 120-124 (2007). (Pubitemid 46898466)
47. Bader P, Burkhard FC, Markwalder R, Studer UE. Is a limited lymph node dissection an adequate staging procedure for prostate cancer? J. Urol. 168(2), 514-518 (2002). (Pubitemid 34793284)
48. Heesakkers RA, Jager GJ, Hovels AM et al. Prostate cancer: detection of lymph node metastases outside the routine surgical area with ferumoxtran-10-enhanced MR imaging. Radiology 251(2), 408-414 (2009).
49. Ross RW, Zietman AL, Xie W et al. Lymphotropic nanoparticle-enhanced magnetic resonance imaging (LNMRI) identifies occult lymph node metastases in prostate cancer patients prior to salvage radiation therapy. Clin. Imaging 33(4), 301-305 (2009).
50. Terakawa T, Miyake H, Kurahashi T, Furukawa J, Takenaka A, Fujisawa M. Improved sensitivity for detecting micrometastases in pelvic lymph nodes by real-time reverse transcriptase polymerase chain reaction (RT-PCR) compared with conventional RT-PCR in patients with clinically localized prostate cancer undergoing radical prostatectomy. BJU Int. 103(8), 1074-1078 (2009).
51. Bolla M, van Poppel H, Collette L et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911).Lancet 366(9485), 572-578 (2005). (Pubitemid 41140332)
52. Bill-Axelson A, Holmberg L, Filen F et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J. Natl Cancer Inst. 100(16), 1144-1154 (2008).
53. Da Pozzo LF, Cozzarini C, Briganti A et al. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy. Eur. Urol. 55(5), 1003-1011 (2009).
54. Schumacher MC, Burkhard FC, Thalmann GN, Fleischmann A, Studer UE. Is pelvic lymph node dissection necessary in patients with a serum PSA (Pubitemid 44038073)
55. Schmid HP. Re: Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy. J. Urol. 157(1), 270 (1997).
56. Sgrignoli AR, Walsh PC, Steinberg GD, Steiner MS, Epstein JI. Prognostic factors in men with stage D1 prostate cancer: identification of patients less likely to have prolonged survival after radical prostatectomy. J. Urol. 152(4), 1077-1081 (1994). (Pubitemid 24283437)
57. Seay TM, Blute ML, Zincke H. Long-term outcome in patients with pTxN+ adenocarcinoma of prostate treated with radical prostatectomy and early androgen ablation. J. Urol. 159(2), 357-364 (1998). (Pubitemid 28049233)
58. Fleischmann A, Schobinger S, Schumacher M, Thalmann GN, Studer UE. Survival in surgically treated, nodal positive prostate cancer patients is predicted by histopathological characteristics of the primary tumor and its lymph node metastases. Prostate 69(4), 352-362 (2009).
59. Ohori M, Wheeler TM, Scardino PT. The New American Joint Committee on Cancer and International Union Against Cancer TNM classification of prostate cancer. Clinicopathologic correlations. Cancer 74(1), 104-114 (1994).
60. Dugan JA, Bostwick DG, Myers RP, Qian J, Bergstralh EJ, Oesterling JE. The definition and preoperative prediction of clinically insignificant prostate cancer. JAMA 275(4), 288-294 (1996). (Pubitemid 26028587)
61. Eichelberger LE, Koch MO, Daggy JK, Ulbright TM, Eble JN, Cheng L. Predicting tumor volume in radical prostatectomy specimens from patients with prostate cancer. Am J. Clin. Pathol. 120(3), 386-391 (2003). (Pubitemid 37295109)
62. McNeal JE. Cancer volume and site of origin of adenocarcinoma in the prostate: relationship to local and distant spread. Hum. Pathol. 23(3), 258-266 (1992).
63. McNeal JE, Bostwick DG, Kindrachuk RA, Redwine EA, Freiha FS, Stamey TA. Patterns of progression in prostate cancer. Lancet 1(8472), 60-63 (1986). (Pubitemid 16182890)
64. McNeal JE, Villers AA, Redwine EA, Freiha FS, Stamey TA. Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate. Cancer 66(6), 1225-1233 (1990). (Pubitemid 20310665)
65. Mettlin CJ, Murphy GP, Babaian RJ et al. Observations on the early detection of prostate cancer from the American Cancer Society National Prostate Cancer Detection Project. Cancer 80(9), 1814-1817 (1997). (Pubitemid 27475943)
66. Anscher MS, Prosnitz LR. Prognostic significance of extent of nodal involvement in stage D1 prostate cancer treated with radiotherapy. Urology 39(1), 39-43 (1992).
67. Gervasi LA, Mata J, Easley JD et al. Prognostic significance of lymph nodal metastases in prostate cancer. J. Urol. 142(2 Pt 1), 332-336 (1989). (Pubitemid 19197108)
68. Golimbu M, Provet J, Al-Askari S, Morales P. Radical prostatectomy for stage D1 prostate cancer. Prognostic variables and results of treatment. Urology 30(5), 427-435 (1987). (Pubitemid 17163647)
69. Hering F, Rist M, Roth J, Mihatsch M, Rutishauser G. Does microinvasion of the capsule and/or micrometastases in regional lymph nodes influence disease-free survival after radical prostatectomy? Br. J. Urol. 66(2), 177-181 (1990). (Pubitemid 20237972)
70. Prout GR Jr, Heaney JA, Griffin PP, Daly JJ, Shipley WU. Nodal involvement as a prognostic indicator in patients with prostatic carcinoma. J.Urol. 124(2), 226-231 (1980). (Pubitemid 10045591)
71. Schmidt JD. Transperineal ultrasound-guided prostate cryosurgery. J. Surg. Oncol. 65(3), 228-229 (1997). (Pubitemid 27351712)
72. Schmidt JD, Gibbons RP, Bartolucci A, Murphy GP. Prognosis in stage D-1 prostate cancer relative to anatomic sites of nodal metastases. National Prostatic Cancer Treatment Group. Cancer 64(8), 1743-1746 (1989). (Pubitemid 19251149)
73. Smith JA Jr, Middleton RG. Implications of volume of nodal metastasis in patients with adenocarcinoma of the prostate. J. Urol. 133(4), 617-619 (1985). (Pubitemid 15100755)
74. Davidson PJ, Hop W, Kurth KH, Fossa SD, Waehre H, Schroder FH. Progression in untreated carcinoma of the prostate metastatic to regional lymph nodes (stage t0 to 4,N1 to 3.M0,D1).European Organization for Research and Treatment of Cancer Genitourinary Group. J. Urol. 154(6), 2118-2122 (1995).
75. deKernion JB, Huang MY, Kaufman JJ, Smith RB. Result of treatment of patients with stage D1 prostatic carcinoma. Urology 26(5), 446-451 (1985). (Pubitemid 17045571)
76. Griebling TL, Ozkutlu D, See WA, Cohen MB. Prognostic implications of extracapsular extension of lymph node metastases in prostate cancer. Mod. Pathol. 10(8), 804-809 (1997). (Pubitemid 27374851)
77. Grossman HB, Batata M, Hilaris B, Whitmore WF Jr. 125I implantation for carcinoma of prostate. Further follow-up of first 100 cases. Urology 20(6), 591-598 (1982). (Pubitemid 13221221)
78. Kramer SA, Cline WA Jr, Farnham R et al. Prognosis of patients with stage D1 prostatic adenocarcinoma. J. Urol. 125(6), 817-819 (1981). (Pubitemid 11083255)
79. Steinberg GD, Epstein JI, Piantadosi S, Walsh PC. Management of stage D1 adenocarcinoma of the prostate: the Johns Hopkins experience 1974 to 1987. J. Urol. 144(6), 1425-1432 (1990).
80. Austenfeld MS, Davis BE. New concepts in the treatment of stage D1 adenocarcinoma of the prostate. Urol. Clin. North Am. 17(4), 867-884 (1990). (Pubitemid 20371345)
81. Cheng CW, Bergstralh EJ, Zincke H. Stage D1 prostate cancer. A nonrandomized comparison of conservative treatment options versus radical prostatectomy. Cancer 71(3 Suppl.), 996-1004 (1993). (Pubitemid 23049623)
82. Ekman P. Dilemma of microscopic lymph node metastases in human prostate cancer. Eur. Urol. 24(Suppl. 2), 57-60 (1993). (Pubitemid 23320405)
83. Hanks GE. The challenge of treating node-positive prostate cancer. An approach to resolving the questions. Cancer 71(3 Suppl.), 1014-1018 (1993). (Pubitemid 23049625)
84. Smith PH. Deferred therapy in patients with advanced disease. Cancer 71(3 Suppl.), 1074-1077 (1993). (Pubitemid 23049634)
85. Zincke H. The role of pathologic variables and hormonal treatment after radical prostatectomy for stage D1 disease. Oncology 5(3), 129-142 (1991).
86. Zincke H, Bergstralh EJ, Larson-Keller JJ etzal. Stage D1 prostate cancer treated by radical prostatectomy and adjuvant hormonal treatment. Evidence for favorable survival in patients with DNA diploid tumors. Cancer 70(1 Suppl.), 311-323 (1992).
87. Sivridis E, Giatromanolaki A, Galazios G, Koukourakis MI. Node-related factors and survival in node-positive breast carcinomas. Breast 15(3), 382-389 (2006). (Pubitemid 43812217)
88. Origoni M, Sideri M, Garsia S, Carinelli SG, Ferrari AG. Prognostic value of pathological patterns of lymph node positivity in squamous cell carcinoma of the vulva stage III and IVA FIGO. Gynecol. Oncol. 45(3), 313-316 (1992).
89. Paladini D, Cross P, Lopes A, Monaghan JM. Prognostic significance of lymph node variables in squamous cell carcinoma of the vulva. Cancer 74(9), 2491-2496 (1994). (Pubitemid 24320853)
90. Nakamura K, Ogoshi K, Makuuchi H. Subclassification of extranodal involvement in gastric cancer patients. Hepatogastroenterology 57(101), 968-974 (2010).
91. Oddone N, Morgan GJ, Palme CE et al. Metastatic cutaneous squamous cell carcinoma of the head and neck: the immunosuppression, treatment, extranodal spread, and margin status (ITEM) prognostic score to predict outcome and the need to improve survival. Cancer 115(9), 1883-1891 (2009).
92. Clayton F, Hopkins CL. Pathologic correlates of prognosis in lymph node-positive breast carcinomas. Cancer 71(5), 1780-1790 (1993). (Pubitemid 23067394)
93. Cybulsky IJ, Lanza LA, Ryan MB, Putnam JB Jr, McMurtrey MM, Roth JA. Prognostic significance of computed tomography in resected N2 lung cancer. Ann. Thorac. Surg. 54(3), 533-537 (1992).
94. Donegan WL, Stine SB, Samter TG. Implications of extracapsular nodal metastases for treatment and prognosis of breast cancer. Cancer 72(3), 778-782 (1993). (Pubitemid 23215265)
95. Mambo NC, Gallager HS. Carcinoma of the breast: the prognostic significance of extranodal extension of axillary disease. Cancer 39(5), 2280-2285 (1977). (Pubitemid 8120413)
96. Monsour PD, Sause WT, Avent JM, Noyes RD. Local control following therapeutic nodal dissection for melanoma. J. Surg. Oncol. 54(1), 18-22 (1993). (Pubitemid 23280246)
97. Frost P, Levin B. Clinical implications of metastatic process. Lancet 339(8807), 1458-1461 (1992).
98. Kohn EC, Liotta LA. Molecular insights into cancer invasion: strategies for prevention and intervention. Cancer Res. 55(9), 1856-1862 (1995).
99. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64(2), 327-336 (1991). (Pubitemid 121001258)
100. Poste G, Fidler IJ. The pathogenesis of cancer metastasis. Nature 283(5743), 139-146 (1980). (Pubitemid 10171124)
101. Brawn PN. The dedifferentiation of prostate carcinoma. Cancer 52(2), 246-251 (1983). (Pubitemid 13063164)
102. Henricks WH, Chu YC, Goldblum JR, Weiss SW. Dedifferentiated liposarcoma: a clinicopathological analysis of 155 cases with a proposal for an expanded definition of dedifferentiation. Am. J. Surg. Pathol. 21(3), 271-281 (1997). (Pubitemid 27120195)
103. Kojiro M, Yano H, Nakashima O. Pathology of early hepatocellular carcinoma: progression from early to advanced. Semin. Surg. Oncol. 12(3), 197-203 (1996). (Pubitemid 26154627)
104. Wheeler JA, Zagars GK, Ayala AG. Dedifferentiation of locally recurrent prostate cancer after radiation therapy. Evidence for tumor progression. Cancer 71(11), 3783-3787 (1993). (Pubitemid 23152698)
105. Brawn P. Histologic features of metastatic prostate cancer. Hum. Pathol. 23(3), 267-272 (1992).
106. Brawn P, Kuhl D, Johnson C 3rd, Pandya P, McCord R. Stage D1 prostate carcinoma. The histologic appearance of nodal metastases and its relationship to survival. Cancer 65(3), 538-543 (1990). (Pubitemid 20058372)
107. Adolfsson J, Tribukait B. Evaluation of tumor progression by repeated fine needle biopsies in prostate adenocarcinoma: modal deoxyribonucleic acid value and cytological differentiation. J. Urol. 144(6), 1408-1410 (1990).
108. Bazinet M, Hamdy SM, Begin LR, Stephenson RA, Fair WR. Prognostic significance of antigenic heterogeneity, Gleason grade, and ploidy of lymph node metastases in patients with prostate cancer. Prostate 20(4), 311-326 (1992).
109. Oefelein MG, Smith N, Carter M, Dalton D, Schaeffer A. The incidence of prostate cancer progression with undetectable serum prostate specific antigen in a series of 394 radical prostatectomies. J. Urol. 154(6), 2128-2131 (1995).
110. Cher ML, Stephenson RA, James BC, Carroll PR. Cellular proliferative fraction of metastatic lymph nodes predicts survival in stage D1 (TxN+M0) prostate cancer. J. Urol. 155(5), 1674-1677 (1996). (Pubitemid 26126974)
111. Babaian RJ, Troncoso P, Bhadkamkar VA, Johnston DA. Analysis of clinicopathologic factors predicting outcome after radical prostatectomy. Cancer 91(8), 1414-1422 (2001). (Pubitemid 32319250)
112. Bahnson RR, Dresner SM, Gooding W, Becich MJ. Incidence and prognostic significance of lymphatic and vascular invasion in radical prostatectomy specimens. Prostate 15(2), 149-155 (1989). (Pubitemid 19262143)
113. de la Taille A, Rubin MA, Buttyan R et al. Is microvascular invasion on radical prostatectomy specimens a useful predictor of PSA recurrence for prostate cancer patients? Eur. Urol. 38(1), 79-84 (2000). (Pubitemid 30418020)
114. Epstein JI, Partin AW, Potter SR, Walsh PC. Adenocarcinoma of the prostate invading the seminal vesicle: prognostic stratification based on pathologic parameters. Urology 56(2), 283-288 (2000). (Pubitemid 30495584)
115. Ferrari MK, McNeal JE, Malhotra SM, Brooks JD. Vascular invasion predicts recurrence after radical prostatectomy: stratification of risk based on pathologic variables. Urology 64(4), 749-753 (2004). (Pubitemid 39446056)
116. Herman CM, Wilcox GE, Kattan MW, Scardino PT, Wheeler TM. Lymphovascular invasion as a predictor of disease progression in prostate cancer. Am. J. Surg. Pathol. 24(6), 859-863 (2000). (Pubitemid 30366274)
117. Ito K, Nakashima J, Mukai M et al. Prognostic implication of microvascular invasion in biochemical failure in patients treated with radical prostatectomy. Urol. Int. 70(4), 297-302 (2003). (Pubitemid 36566261)
118. McNeal JE, Yemoto CE. Significance of demonstrable vascular space invasion for the progression of prostatic adenocarcinoma. Am. J. Surg. Pathol. 20(11), 1351-1360 (1996). (Pubitemid 26367206)
119. Salomao DR, Graham SD, Bostwick DG. Microvascular invasion in prostate cancer correlates with pathologic stage. Arch. Pathol. Lab. Med. 119(11), 1050-1054 (1995). (Pubitemid 26063813)
120. Shariat SF, Khoddami SM, Saboorian H et al. Lymphovascular invasion is a pathological feature of biologically aggressive disease in patients treated with radical prostatectomy. J. Urol. 171(3), 1122-1127 (2004). (Pubitemid 38327540)
121. van den Ouden D, Hop WC, Kranse R, Schroder FH. Tumour control according to pathological variables in patients treated by radical prostatectomy for clinically localized carcinoma of the prostate. Br. J. Urol. 79(2), 203-211 (1997). (Pubitemid 127798048)
122. van den Ouden D, Kranse R, Hop WC, van der Kwast TH, Schroder FH. Microvascular invasion in prostate cancer: prognostic significance in patients treated by radical prostatectomy for clinically localized carcinoma. Urol. Int. 60(1), 17-24 (1998). (Pubitemid 28072434)
123. Bastide C, Brenot-Rossi I, Garcia S, Rossi D. Radioisotope guided sentinel lymph node dissection in patients with localized prostate cancer: results of the first 100 cases. Eur J. Surg. Oncol. 35(7), 751-756 (2009).
124. Heidenreich A, Elert A, Hofmann R. Ibandronate in the treatment of prostate cancer associated painful osseous metastases. Prostate Cancer Prostatic Dis. 5(3), 231-235 (2002).
125. Stone NN, Stock RG, Unger P. Laparoscopic pelvic lymph node dissection for prostate cancer: comparison of the extended and modified techniques. J. Urol. 158(5), 1891-1894 (1997). (Pubitemid 27433173)
126. Clark T, Parekh DJ, Cookson MS et al. Randomized prospective evaluation of extended versus limited lymph node dissection in patients with clinically localized prostate cancer. J. Urol. 169(1), 145-147 (2003). (Pubitemid 35461573)
127. Wawroschek F, Vogt H, Weckermann D, Wagner T, Hamm M, Harzmann R. Radioisotope guided pelvic lymph node dissection for prostate cancer. J. Urol. 166(5), 1715-1719 (2001). (Pubitemid 32953393)
128. Hacker A, Jeschke S, Leeb K et al. Detection of pelvic lymph node metastases in patients with clinically localized prostate cancer: comparison of [18F]fluorocholine positron emission tomography-computerized tomography and laparoscopic radioisotope guided sentinel lymph node dissection. J. Urol. 176(5), 2014-2019 (2006). (Pubitemid 44633154)
129. Janetschek G. Can sentinel pelvic lymph node dissection replace extended pelvic lymph node dissection in patients with prostate cancer? Nat. Clin. Pract. Urol. 4(12), 636-637 (2007). (Pubitemid 350238064)
130. Jeschke S, Beri A, Grull M et al. Laparoscopic radioisotope-guided sentinel lymph node dissection in staging of prostate cancer. Eur. Urol. 53(1), 126-132 (2008).
131. Weckermann D, Dorn R, Trefz M, Wagner T, Wawroschek F, Harzmann R. Sentinel lymph node dissection for prostate cancer: experience with more than 1,000 patients. J. Urol. 177(3), 916-920 (2007). (Pubitemid 46216337)
132. Jeschke S, Nambirajan T, Leeb K, Ziegerhofer J, Sega W, Janetschek G. Detection of early lymph node metastases in prostate cancer by laparoscopic radioisotope guided sentinel lymph node dissection. J. Urol. 173(6), 1943-1946 (2005). (Pubitemid 40675217)
133. Harisinghani MG, Barentsz J, Hahn PF et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N. Engl. J. Med. 348(25), 2491-2499 (2003). (Pubitemid 36706536)
134. Flanigan RC, McKay TC, Olson M, Shankey TV, Pyle J, Waters WB. Limited efficacy of preoperative computed tomographic scanning for the evaluation of lymph node metastasis in patients before radical prostatectomy. Urology 48(3), 428-432 (1996). (Pubitemid 26317484)
135. Tempany CM, McNeil BJ. Advances in biomedical imaging. JAMA 285(5), 562-567 (2001). (Pubitemid 32656324)
136. Pouliot F, Johnson M, Wu L. Non-invasive molecular imaging of prostate cancer lymph node metastasis. Trends Mol. Med. 15(6), 254-262 (2009).
137. Hricak H, Dooms GC, Jeffrey RB et al. Prostatic carcinoma: staging by clinical assessment, CT, and MR imaging. Radiology 162(2), 331-336 (1987). (Pubitemid 17015632)
138. Katz-Brull R, Lavin PT, Lenkinski RE. Clinical utility of proton magnetic resonance spectroscopy in characterizing breast lesions. J. Natl Cancer Inst. 94(16), 1197-1203 (2002). (Pubitemid 34993869)
139. Kurhanewicz J, Vigneron DB, Males RG, Swanson MG, Yu KK, Hricak H. The prostate: MR imaging and spectroscopy. Present and future. Radiol. Clin. North Am. 38(1), 115-138 (2000). (Pubitemid 30059008)
140. Wunderbaldinger P, Josephson L, Bremer C, Moore A, Weissleder R. Detection of lymph node metastases by contrast-enhanced MRI in an experimental model. Magn. Reson. Med. 47(2), 292-297 (2002). (Pubitemid 34116797)
141. Koh DM, Cook GJ, Husband JE. New horizons in oncologic imaging. N. Engl. J. Med. 348(25), 2487-2488 (2003). (Pubitemid 36706534)
142. Miller MC, Doyle GV, Terstappen LW. Significance of circulating tumor cells detected by the cellsearch system in patients with metastatic breast colorectal and prostate cancer. J. Oncol. 2010, 617421 (2010).
143. Garcia JA, Rosenberg JE, Weinberg V et al. Evaluation and significance of circulating epithelial cells in patients with hormone-refractory prostate cancer. BJU Int. 99(3), 519-524 (2007). (Pubitemid 46238821)
144. Danila DC, Heller G, Gignac GA et al. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin. Cancer Res. 13(23), 7053-7058 (2007). (Pubitemid 350276887)
145. Moreno JG, Miller MC, Gross S, Allard WJ, Gomella LG, Terstappen LW. Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology 65(4), 713-718 (2005). (Pubitemid 40523005)
146. de Bono JS, Scher HI, Montgomery RB et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin. Cancer Res. 14(19), 6302-6309 (2008).
147. Epstein JI, Partin AW, Sauvageot J, Walsh PC. Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. Am. J. Surg. Pathol. 20(3), 286-292 (1996). (Pubitemid 26071509)
148. Bader P, Burkhard FC, Markwalder R, Studer UE. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J. Urol. 169(3), 849-854 (2003). (Pubitemid 36188105)
149. McCullough DL, Leadbetter WF. Radical pelvic surgery for locally extensive carcinoma of the prostate. J. Urol. 108(6), 939-943 (1972).
150. Briganti A, Karnes JR, Da Pozzo LF et al. Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. Eur. Urol. 55(2), 261-270 (2009).